Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Части VI-VII

Достижения в лечении онкологических заболеваний привели к повышению выживаемости больных со злокачественными новообразованиями. В то же время противоопухолевая терапия сопряжена с риском развития побочных эффектов, среди которых сердечно-сосудистые осложнения занимают лидирующие позиции. Дисфункция левого желудочка и сердечная недостаточность, артериальная гипертония, ишемия миокарда, нарушения ритма сердца, тромбоэмболии и другие сердечно-сосудистые осложнения могут препятствовать проведению жизненно важной противоопухолевой терапии, снижать выживаемость и качество жизни больных. В представленном руководстве отражены диагностические и терапевтические подходы к ведению больных онкологического профиля, получающих потенциально кардиотоксичную противоопухолевую терапию. Представленные части руководства посвящены вопросам диагностики, профилактики и лечения тромбоэмболических осложнений, связанных с противоопухолевой терапией, и осложнений лучевой терапии.

химиотерапия, лучевая терапия, тромбозы, кардиотоксичность, диагностика, профилактика, лечение

1. Green K.B, Silverstein R.L. Hypercoagulobility in cancer. Hemat Onc Clin N Am 1996; 10: 499-530.

2. Hillen H.F. Thrombosis in cancer patients. ESMO Ann Oncol 2000; 11 (Suppl. 3): 273-6.

3. Levine M.N, Lee A.Y, Kakkar A.K. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting, 2005, May 13-17; р. 748-77.

4. Bromberg M.E, Cappello M. Cancer and blood coagulation: molecular aspects. Cancer 1999; 3: 132-8.

5. Falanga A, Tickles F.R. Pathophysiology of the thrombotic state in the cancer patient. Semin Thromb Haemostas 1999; 25: 173-82.

6. Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.

7. Roffi M, Patrono C, Collet J.P et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315.

8. Steg P.G, James S.K, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.

9. Moore R.A, Adel N, Riedel E et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncology 2011; 29: 3466-473.

10. Zamorano J.L, Lancellotti Р, Munoz D.R et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37: 2768-801.

11. Haugnes H.S, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testricular cancer: a 20-year follow-up study. J Clin Oncology 2010; 28: 4649-57.

12. Huddart R.A, Norman A, Shahidi M et al. Cardiovascular disease as long-termcomplication of treatment for testicular cancer. J Clin Oncology 2003; 21: 1513-23.

13. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomized, phase 3 trial. Lancet Oncol 2013; 14: 933-42.

14. Levine G.N, Bates E.R, Bittl J.A et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation 2016; 134: 123-55.

15. Khorana A.A, Connolly G.C. Assessing risk of venous thromboembolism in the patient with cancer. Clin Oncol 2009; 27: 4839-47.

16. Андрияшкин В.В., Кириенко А.И., Явелов И.С. и др. Российские клинические рекомендации по профилактике и лечению венозных тромбоэмболических осложнений у онкологических больных. 2014; с. 10-1.

17. Khorana A.A, Carrier M, Garcia D.A et al. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Tromb Thrombolysis 2016; 41: 81-91.

18. Kucher N, Koo S, Quiroz R et al. Electronic Alerts to Prevent Venou Thromboembolism among Hospitalized Patients. N Engl J Med 2005; 352: 969-77.

19. Lyman G.H, Khorana A, Kuderer N.M et al. Venous thromboembolism prophilaxis and treatment in patients with cancer; American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17): 2189-204.

20. Чазова И.Е., Тюляндин С.А., Виценя М.В. и др. Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Часть I. Системные гипертензии. 2017; 14 (3): 6-20.

21. Khorana A.A, Kuderer N.M, Culakova E. Development and Validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10): 4902-7.

22. Khorana A.A. Risk assessment and profilaxis for VTE in cancer patients. Natl Compr Canc Netw 2011; 9: 789-97.

23. Watson H.G et al. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 2015; 170: 640-8.

24. Schulman S, Goldhaber S.Z, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114: 150-7.

25. Prins M.H, Lensing A.W, Brighton T.A et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1): e37-46.

26. Vedovati M.C, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (2): 475-83.

27. Gerotziafas G.T, Mahe I, Elalamy I. New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag 2014; 10: 423-36.

28. Kearon C, Akl E.A, Ornelas J et al. Antithrombotic Therapy for VTE Disease. Chest Guidelines and Expert Panel Report. Chest 2016; 149 (2): 315-52.

29. Gagliardi G, Constine L.S, Moiseenko V et al. Radiation Dose-Volume Effects in the Heart. Int J Radiat Oncol Biol Phys 2010; 76 (3; Suppl.): 77-85.

30. Aleman B.M.P, van den Belt-Dusebout A.W, Klokman W.J et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003; 21: 3431-9.

31. Darby S.C, Cutter D.J, Boerma M et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 2010; 76: 656-65.

32. Wei X, Liu H.H, Tucker S.L et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008; 70: 707-14.

33. Jaworski C, Mariani J.A, Wheeler G, Kaye D.M. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61: 2319-28.

34. Aleman B.M, van den Belt-Dusebout A.W, De Bruin M.L et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878-86.

35. Taylor C.W et al. Cardiac exposures in breast cancer radiotherapy: 1950’s-1990’s. Int J Radiat Oncol Biol Phys 2007; 69: 1484-95.

36. Cuzick J, Stewart H, Peto R et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 1987; 71: 15-29.

37. Paszat L.F, Mackillop W.J, Groome P.A et al. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol 1998; 16: 2625-31.

38. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995; 333 (22): 1444-55.

39. Clarke M, Collins R, Darby S et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-106.

40. Giordano S.H, Kuo Y.F, Freeman J.L et al: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005; 97 (6): 419-24.

41. Hooning M, Botma A, Aleman B et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365-75.

42. Borger J.N, Hooning M.J, Boersma L.J. et al. Cardiotoxic effects of tangential breast irradiation in early breast patients: The role of irradiated heart volume. Inst J Radiat Oncol Biol Phys 2007; 69 (4): 1131-8.

43. Darby S.C, McGale P, Taylor C.W, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-65.

44. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Darby S, McGale P, Correa C et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804): 1707-16.

45. Patt D.A, Goodwin J.S., Kuo Y.E et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005; 23 (30): 7475-82.

46. Wright G.P, Drinane J.J. Left-Sided Breast Irradiation does not Result in Increased Long-Term Cardiac-Related Mortality Among Women Treated with Breast-Conserving Surgery. Ann Surg Oncol 2016, 23: 1117-22.

47. Schultz-Hector S, Trott K.R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data. Int J Radiat Oncol Biol Phys 2007; 67: 10-8.

48. Wu W, Masri A, Popovic Z.B et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation 2013; 127: 1476-84.

49. Hancock S, Tucker M, Hoppe R. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993; 270: 1949-55.

50. Carver J.R, Shapiro C.L, Ng A. et al. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25: 3991-4008.

51. Meyer R, Gospodarowicz M, Connors J. et al. NCIC Clinical Trials Group, Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012; 366: 399-408.

52. Lee C.K, Aeppli D, Nierengarten M.E. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000; 48: 169-79.

53. Lancellotti P, Nkomo V.T, Badano L.P. et al. European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14: 721-40.

54. Ridker P.M, Buring J.E, Rifai N. et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds score. J Am Med Assoc 2007; 297 (6): 611-9.

55. Darby S.C, Ewertz M, McGalle P. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-98.

56. Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys 2007; 69: 483-89.

57. Shapiro C, Hardenbergh P, Gelman R et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998; 16: 3493-501.

58. Hull M.C, Morris C.G, Pepine C.J, Mendenhall N.P. Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated With Radiation Therapy. JAMA 2003; 290 (21): 2831-37.

59. Marks L.B, Yu X, Prosnitz R.G et al. The incidence functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005; 63 (1): 214-23.

60. Van Nimwegen F.A, Schaapveld M, Janus C.P. et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015; 175: 1007-17.

61. Paszat L.F, Mackillop W.J, Groome P.A. Mortality from myocardial infarction following postmastectomy radiotherapy for breast cancer: A population-based study in Ontario, Canada. Inst J Radiat Oncol Biol Phys 1999; 43 (2): 755-61.

62. King V, Constine L, Clark D et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1996; 36: 881-9.

63. Heidenreich P, Kapoor J. Radiation induced heart disease: systemic disorders in heart disease. Heart 2009; 95: 252-8.

64. Harris E.E, Correa C, Hwang W.T. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006; 24 (25): 4100-6.

65. Baker J.E, Moulder J.E, Hopewell J.W. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal 2011; 15: 1945-56.

66. Taunk N.K, Haffty B.G, Kostis J.B, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol 2015; 5: 39.

67. Boerma M, Hauer-Jensen M. Preclinical research into basic mechanisms of radiation-induced heart disease. Cardiol Res Pract 2011. DOI: 10.4061/2011/858262

68. Stewart F, Hoving S, Russell N. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 2010; 174: 865-9.

69. Yusuf S, Sami S, Daher I. Radiation-induced heart disease: a clinical update. Cardiol Res Pract 2011; Article ID 317659.

70. Stewart F, Heeneman S, Te Poele J et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE2/2 mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol 2006; 168: 649-58.

71. Hardenbergh P.H, Munley M.T, Bentel G.C et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 2001; 49: 1023-8.

72. Gomez D.R, Yusuf S.W, Munsell M et al. A Prospective Exploratory Analysis of Cardiac Biomarkers and Electrocardiogram Abnormalities in Patients Receiving Thoracic Radiation Therapy with High-Dose Heart Exposure. J Thorac Oncol 2014; 9 (10): 1554-60.

73. Erven K, Florian A, Slagmolen P, Sweldens C et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys 2013; 85 (5): 1172-8.

74. Armstrong G.T, Joshi V.M, Ness K.K et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015; 65: 2511-22.

75. Nagueh S, Appleton C, Gillebert T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-93.

76. Constine L, Schwartz R, Savage D et al. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1997; 39: 897-906.

77. DePasquale E.C, Nasir K, Jacoby D.L. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant 2012; 31 (12): 1269-75.

78. McGale P, Darby S.C, Hall P et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011; 100: 167-75.

79. Virmani R, Farb A, Carter A.J, Jones R.M. Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin Interv Cardiol 1998; 3: 163-72.

80. Brosius F.C. 3rd, Waller B.F, Roberts W.C. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70: 519-530.

81. Veinot J.P, Edwards W.D. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 1996; 27: 766-73.

82. McEniery P.T, Dorosti K, Schiavone W.A et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol 1987; 60: 1020-4.

83. Hering D, Faber L, Horstkotte D. Echocardiographic features of radiation-associated valvular disease. Am J Cardiol 2003; 92: 226-30.

84. Brouwer C.A, Postma A, Hooimeijer HL et al. Endothelial damage in long-term survivors of childhood cancer. J Clin Oncol 2013; 31: 3906-13.

85. Correa C.R, Litt H.I, Hwang W.T et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for earlystage breast cancer. J Clin Oncol 2007; 25: 3031-7.

86. Storey M.R, Munden R, Strom E.A. et al. Coronary artery dosimetry in intact left breast irradiation. Cancer J 2001; 7: 492-7.

87. Van Nimwegen F.A, Schaapveld M, Cutter D.J et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016; 34: 235-43.

88. De Haas EC., Oosting S.F, Lefrandt J.D et al. The metabolic syndrome in cancer survivors. Lancet Oncol 2010; 11: 193-203.

89. Oeffinger K.C, Mertens A.C, Sklar C.A et al. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-82.

90. Orzan F, Brusca A, Conte M.R et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 1993; 69: 496-500.

91. Vijayakumar S, Rosenberg I, Spelbring D, Brandt T. Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin’s disease. Med Dosim 1991; 16: 237-41.

92. Prosnitz R.G, Hubbs J.L, Evans E.S et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 2007; 110: 1840-50.

93. Gyenes G, Fornander T, Carlens P et al. Detection of radiation-induced myocardial damage by technetium-99 m sestamibi scintigraphy. Eur J Nucl Med 1997; 24: 286-92.

94. Haugnes H.S, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649-57.

95. Malanca M, Cimadevilla C, Brochet E et al. Radiotherapy-induced mitral stenosis: a three-dimensional perspective. J Am Soc Echocardiogr 2010; 23 (108): e101-102.

96. Plana J.C, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15: 1063-93.

97. Carlson R.G, Mayfield W.R, Normann S, Alexander JA. Radiation-associated valvular disease. Chest 1991; 99: 538-45.

98. Glanzmann C, Huguenin P, Lutolf U.M. et al. Cardiac lesions after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1994; 30: 43-54.

99. Brand M.D, Abadi C.A, Aurigemma G.P et al. Radiation-associated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain. J Heart Valve Dis 2001; 10: 681-5.

100. Katz N.M, Hall A.W, Cerqueira M.D. Radiation induced valvulitis with late leaflet rupture. Heart 2001; 86: E20.

101. Pohjola-Sintonen S, Totterman K.J, Salmo M, Siltanen P. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer 1987; 60: 31-7.

102. Cutter D.J, Schaapveld M, Darby S.C. et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 2015; 107: djv008.

103. Groarke J.D, Nguyen P.L, Nohria A et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for noninvasive imaging for detection of cardiovascular disease. Eur Heart J 2014; 35: 612-23.

104. Vahanian A, Alfieri O, Andreotti F et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-96.

105. De Bruin M.L, Dorresteijn L.D, van’t Veer M.B et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009; 101: 928-37.

106. Yuan H, Gaber M.W, Boyd K. et al. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys 2006; 66: 860-6.

107. Louis E.L, McLoughlin M.J, Wortzman G. Chronic damage to medium and large arteries following irradiation. J Can Assoc Radiol 1974; 25: 94-104.

108. Fajardo L.F. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005; 44: 13-22.

109. Jurado J.A, Bashir R, Burket M.W. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv 2008; 72: 563-8.

110. Tendera M, Aboyans V, Bartelink M.L et al. European Stroke Organisation, ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851-906.

111. Fokkema M, den Hartog A.G, Bots M.L et al. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke 2012; 43: 793-801.

112. Gujral D.M, Shah B.N, Chahal N.S. et al. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol) 2014; 26: 94-102.

113. Adler Y, Charron P, Imazio M. et al. European Society of Cardiology. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36: 2921-64.

114. Stewart J.R, Fajardo L.F, Gillette S.M, Constine L.S. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31: 1205-11.

115. Applefeld M.M, Wiernik P.H. Cardiac disease after radiation therapy for Hodgkin’s disease: analysis of 48 patients. Am J Cardiol 1983; 51: 1679-81.

116. Maisch B, Ristic A, Pankuweit S. Evaluation and Management of Pericardial Effusion in Patients with Neoplastic Disease. Prog Cardiovasc Dis 2010; 53 (2): 157-63.

117. Welch T.D, Ling L.H, Espinosa R.E et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging 2014; 7: 526-34.

118. Bertog S.C, Thambidorai S.K, Parakh K et al. Constrictive Pericarditis: Etiology and Cause-Specific Survival After Pericardiectomy. J Am Coll Cardiol 2004; 43: 1445-52.

119. Ness K.K, Armstrong G.T. Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. J Am Coll Cardiol 2015; 65: 584-5.

120. Bentzen S.M, Constine L.S, Deasy J.O. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010; 76 (Suppl. 3): S3-9.

121. Prosnitz R.G, Chen Y.H, Marks L.B. Cardiac toxicity following thoracic radiation. Semin Oncol 2005; 32 (2; Suppl. 3): S71-S80.

122. Louwe R.J, Wendling M, van Herk M.B, Mijnheer B.J. Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. Med Phys 2007; 34: 1354-63.

123. McDonald M.W, Godette K.L, Whitaker D.J et al. Three-year outcomes of breast. intensity-modulated radiation therapy with. simultaneous integrated boost. Int J Radiat Oncol Biol Phys 2010; 77: 523-30.

124. Tan W, Liu D, Xue C et al. Anterior myocardial territory may replace the heart as organ at risk in intensity-modulated radiotherapy for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1689-97.

125. Baycan D, Karacetin D, Balkanay A.Y. et al. Field-in-field IMRT versus 3D-CRT of the breast. Cardiac vessels, ipsilateral lung, and contralateral breast absorbed doses in patients with left-sided lumpectomy: a dosimetric comparison. Jpn J Radiol 2012; 30: 819-23.

126. Bruzzaniti V, Abate A, Pinnaro P et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res 2013; 32: 88.

127. Xu Q, Chen Y, Grimm J et al. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys 2012; 39: 6621-8.

128. Bartlett F.R, Colgan R.M, Donovan E.M et al. HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiother Oncol 2015; 114: 66-72.

129. Utehina O. Healthy tissue sparing postoperative radiotherapy for treatment of early stage breast cancer. Summary of the doctoral thesis. Riga, 2009; p. 32.

130. Трофимова О.П., Чебан О.И., Михина З.П. Кардиоваскулярные осложнения у больных РМЖ после органосохраняющего лечения. Мед. радиология и радиационная безопасность. 2015; 1: 33-8.

131. Piepoli M.F, Hoes A.W, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. DOI: 10.1093/eurheartj/ehw106

132. Ewer M.S, Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 2008; 26: 1201-3.

133. Lenihan D.J, Cardinale D.M. Late cardiac effects of cancer treatment. J Clin Oncol 2012; 30: 3657-64.

134. Heidenreich P.A, Hancock S.L, Lee B.K. et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42: 743-9.

135. Koppelmans V, Vernooij M.W, Boogerd W et al. Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol 2015; 33: 588-93.

136. Copeland K.A, Hosmane V.R, Jurkovitz C et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol 2013; 36: 217-21.

137. Machann W, Beer M, Breunig M et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 2011; 79: 1117-23.